Direct Oral Anticoagulants/Selected Anticoagulants (Vitamin K Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Very Serious. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
All of these medicines can affect your blood's ability to clot.
What might happen:
Taking these medicines together or within a short time of each other may increase your risk of bleeding, including bleeding from your gums, nosebleeds, unusual bruising, or dark stools.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together.Let your doctor know right away if you have any bleeding episodes or signs of bleeding.If your doctor is changing you from one anticoagulant to another, be sure to follow any special instructions you receive about this change.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Eliquis (apixaban) Australian prescribing information. Bristol-Myers Squibb Australia Pty. Ltd. July 21, 2011.
- 2.Eliquis (apixaban) Canadian prescribing information. Bristol-Myers Squibb-Pfizer March 12, 2019.
- 3.Eliquis (apixaban) UK summary of product characterstics. Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb House May, 2021.
- 4.Eliquis (apixaban) US prescribing information. Bristol-Myers Squibb Company April, 2021.
- 5.Bevyxxa (betrixaban) US prescribing information. Portola Pharmaceuticals, Inc. July, 2019.
- 6.Pradaxa (dabigatran etexilate mesilate) UK summary of product characteristics. Boehringer Ingelheim Limited January 10, 2020.
- 7.Pradaxa (dabigatran etexilate mesylate) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. June, 2021.
- 8.Pradax (dabigatran etexilate mesilate) Canadian prescribing information. Boehringer Ingelheim March, 23 2020.
- 9.Savaysa (edoxaban) US prescribing information. Daiichi Sankyo, Inc August, 2019.
- 10.Lixiana (edoxaban) Canadian product monograph. Servier Canada Inc. January 12, 2017.
- 11.Lixiana (edoxaban tosilate) UK summary of product characteristics. Daiichi Sankyo UK Limited July 2, 2015.
- 12.Xarelto (rivaroxaban) US prescribing information. Janssen Pharmaceuticals, Inc. March, 2020.
- 13.Xarelto (rivaroxaban) UK summary of product characteristics. Bayer plc August, 2021.
- 14.Xarelto (rivaroxaban) Canadian prescribing information. Bayer July 20, 2015.
- 15.Xarelto (rivaroxaban) Australian prescribing information. BAYER AUSTRALIA LTD December, 2022.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.